Trump's Tariff Threat: A Potential Disruption to Pharmaceuticals and Global Supply Chains

Strategic Insights -

President Donald Trump's plan to impose hefty import taxes on pharmaceuticals, a category previously largely spared in his trade war, has sparked alarm in the industry. The threat of tariffs up to 200% may disrupt complex supply chains, drive foreign-made generic drugs out of the U.S. market, and create shortages. U.S. and European leaders have detailed a 15% tariff rate on some European goods, including pharmaceuticals, which could have far-reaching consequences for consumers and the global economy.

Key Takeaways:

  • Trump's tariff threat could increase U.S. drug prices by 10% to 14% as stockpiles dwindle, according to Diederik Stadig, a healthcare economist at ING.
  • The U.S. trade deficit in medicinal and pharmaceutical products was nearly $150 billion last year, with many operations having moved overseas to take advantage of lower costs in China and India.
  • The COVID-19 experience highlighted the dangers of relying on foreign countries for medicine and medical supplies, with the U.S. administration recently concluding that importing drugs and pharmaceutical ingredients affects national security.
  • Trump wants to bring pharmaceutical factories back to the United States, but building a factory from scratch is expensive and can take several years, and building in the U.S. wouldn't necessarily protect a drugmaker from tariffs on imported ingredients.
  • Brand-name drug companies have fat profit margins that provide flexibility to absorb costs, while generic drug manufacturers do not, and some may decide to leave the U.S. market rather than pay tariffs.
  • Generic drug manufacturers account for 92% of U.S. retail and mail-order pharmacy prescriptions, and a production pause at a factory in India led to a chemotherapy shortage that disrupted cancer care.

Statistics:

  • The U.S. trade deficit in medicinal and pharmaceutical products was nearly $150 billion last year (20236).
  • Trump's tariffs could increase U.S. drug prices by 10% to 14% as stockpiles dwindle (ING analysis).
  • 97% of antibiotics, 92% of antivirals, and 83% of the most popular generic drugs contain at least one active ingredient that is manufactured abroad (Jacob Jensen, trade policy analyst at the American Action Forum).
  • Generic drug manufacturers account for 92% of U.S. retail and mail-order pharmacy prescriptions (Brookings Institute data).

Sources:

  • Trump announced his plan to impose tariffs on pharmaceuticals, with a 15% tariff rate on some European goods, including pharmaceuticals (Washington AP).
  • Diederik Stadig, healthcare economist at ING, wrote in a commentary that tariffs could increase U.S. drug prices by 10% to 14% as stockpiles dwindle (ING analysis).
  • Jacob Jensen, trade policy analyst at the American Action Forum, noted that 97% of antibiotics, 92% of antivirals, and 83% of the most popular generic drugs contain at least one active ingredient that is manufactured abroad (American Action Forum analysis).
  • Marta Wosińska, health policy analyst at the Brookings Institution, said that tariffs alone are unlikely to persuade generic drug manufacturers to build U.S. factories (Brookings Institute analysis).
  • AP Health Writer Matthew Perrone contributed to this report (AP Health Writer).